Agilux Laboratories

Charles River Laboratories acquires Agilux Laboratories for $64 million

Thursday, September 29, 2016

Charles River Laboratories International has acquired Agilux Laboratories, a Worcester, Massachusetts-based CRO that provides a suite of integrated discovery small and large molecule bioanalytical services, drug metabolism and pharmacokinetic (DMPK) services and pharmacology services. The company’s unique combination of early-stage services enhances the flexibility and speed of its biopharmaceutical clients’ lead identification, optimization, and candidate selection efforts. Agilux was acquired from a holding company controlled by the company’s founders and Ampersand Capital Partners, its only institutional investor.

[Read More]

Agilux Laboratories expands in vivo pharmacokinetics services

Monday, December 9, 2013

New England-based CRO Agilux Laboratories, a provider of drug metabolism and pharmacokinetics (DMPK) services to sponsors, has expanded its in vivo pharmacokinetics services to support clients’ demands and increased service requirements. The space expansion will allow Agilux to significantly increase its capacity and volume, while maintaining fast study starts.

[Read More]